Researchers at the University of Virginia School of Medicine have identified an unexpected contributor to rheumatoid arthritis that may help explain the painful flare-ups associated with the disease. The discovery points to a potential new treatment for the autoimmune disorder and may also allow the use of a simple blood test to detect people at elevated risk for developing the condition.
The promising discovery is among the first to emerge from the School of Medicine’s new affiliation with Inova Health, a collaboration that aims to make medical breakthroughs and advance the battle against disease. In this case, the arthritis discovery originated in the lab of UVA’s Kodi Ravichandran, PhD, and was facilitated by combining his team’s resources and expertise with that of Inova researcher Thomas Conrads, PhD, through a THRIV UVA-Inova seed grant.
Understanding Rheumatoid Arthritis
The new findings about rheumatoid arthritis came in an unexpected fashion. Sanja Arandjelovic, PhD, a research scientist in the Ravichandran group, was seeking to better understand what causes the inflammation associated with inflammatory arthritis when she noted that deleting a gene called ELMO1 alleviated arthritis symptoms in mice. This was particularly surprising because Arandjelovic and Ravichandran initially thought that loss of ELMO1 would result in increased inflammation.
“This was a complete surprise to us initially,” recalled Ravichandran, chairman of UVA’s Department of Microbiology, Immunology and Cancer Biology. “I love those kinds of results, because they tell us that, first, we did not fully comprehend the scientific problem when we began exploring it, and, second, such unexpected results challenge us to think in a different way. Given that rheumatoid arthritis affects millions of people worldwide, we felt the need to understand this observation better.”
Digging deeper into the unusual outcome, the researchers determined that ELMO1 promotes inflammation via their function in white blood cells called neutrophils. Ravichandran described neutrophils as the body’s “first line of defense” because they sense and respond to potential threats. “Normally they are good for us, against many bacterial infections,” he said. “But also there are many times when they produce a lot of friendly fire that is quite damaging to the tissues – when they hang around too long or there are too many neutrophils coming in – in this case, infiltrating into the joints during arthritis.”
The researchers also discovered that there is a natural variation in the ELMO1 gene that can prompt neutrophils to become more mobile and have the potential to invade the joints in greater numbers and induce inflammation. (The potential blood test would detect this variation.)
Here things take a particularly cool turn: Normally, doctors are reluctant to try to block the effect of genes like ELMO1 in people, because such genes can play diverse roles in the body. But Ravichandran believes that ELMO1 is different. “ELMO1 partners with very specific set of proteins only in the neutrophils but not in other cells types we tested,” he said. “So, presumably, you may be able to affect only a select cell type.” This latter result came about from a collaborative study where Conrads’ group at Inova performed sophisticated analysis of ELMO1 proteomic partners in neutrophils, many of which also have previously known links to human arthritis. This provided further validation for the role of ELMO1 in rheumatoid arthritis.
Encouragingly, blocking ELMO1 in lab mice alleviated arthritis inflammation without causing other problems, Ravichandran noted. His laboratory is now seeking to identify drugs that could inhibit the function of ELMO1 and is also designing a test for the variation (also called polymorphism) in the ELMO1 gene.
“This is another example of how fundamental basic research can lead to novel discoveries on clinically relevant problems that affect a large number of people,” Ravichandran said.
The Latest on: Rheumatoid arthritis
via Google News
The Latest on: Rheumatoid arthritis
- Small Molecule Therapies for Rheumatoid Arthritis Market Research With Method, Top Companies, Global Development Factors,and Forecast 2026on February 24, 2021 at 2:03 am
Market Research Engine has published a new report titled as " Small Molecule Therapies for Rheumatoid Arthritis Market Size, By Product (Disease Modifying Anti-Rheumatic Drugs, Non-Steroidal ...
- Risk for rheumatoid arthritis reduced for patients with T2DMon February 23, 2021 at 10:48 am
(HealthDay)—Patients with type 2 diabetes mellitus (T2DM) have a reduced risk for rheumatoid arthritis (RA), which may be due to statin use, according to a study published online Feb. 16 in ...
- Rheumatoid arthritis drug shows promise in fighting Covid-19on February 23, 2021 at 3:00 am
A new study shows an anti-inflammatory drug can help treat certain severe symptoms of Covid-19, and adds a tool for helping the sickest patients ...
- My Rheumatoid Arthritis Inspired Me To Become A Personal Traineron February 19, 2021 at 7:24 am
Before I was even in kindergarten, I was diagnosed with rheumatoid arthritis (RA)—an autoimmune disorder that causes a painful swelling in your joints and can even damage other organs, like your eyes, ...
- Rheumatoid Arthritis (RA) Drugs Market 2020 Driving Factors, Industry Growth, Key Vendors and Forecast to 2025on February 18, 2021 at 10:05 pm
Selbyville, Delaware, Global Rheumatoid Arthritis (RA) Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.4% in the forecast period of 2020 to ...
- A synovial biopsy–driven trial in rheumatoid arthritison February 18, 2021 at 2:45 pm
Some patients with rheumatoid arthritis respond to treatment with rituximab, a B cell–depleting antibody given after other therapies fail, whereas others show poor responses. At present there are no ...
- Why People with Rheumatoid Conditions Should Get COVID-19 Vaccine Soonon February 18, 2021 at 1:48 pm
Experts urge people with rheumatoid arthritis, lupus, and other conditions to get vaccinated because they face a higher risk with COVID-19.
- A two-herb formula inhibits hyperproliferation of rheumatoid arthritis fibroblast-like synoviocyteson February 16, 2021 at 3:56 am
Fibroblast-like synoviocytes (FLS) play a pathogenic role in rheumatoid arthritis (RA). STAT3 signaling is activated in FLS of RA patients (RA-FLS), which in turn causes RA-FLS hyperproliferation. RL ...
- US Rheumatoid Arthritis Drug Market Patent Price Insight Report 2026on February 15, 2021 at 2:00 am
PRNewswire/ -- "US Rheumatoid Arthritis Drug Market, Dosage, Price, Sales Insight 2021 - 2026". Report Highlights: US Rheumatoid Arthritis Drugs Market ...
- Rheumatoid arthritis treatment: Evening primrose oil could alleviate morning stiffnesson February 12, 2021 at 5:45 am
RHEUMATOID arthritis is a long-term condition that causes pain, swelling and stiffness in the joints. Evidence shows that applying evening primrose oil can help to alleviate morning stiffness.
via Bing News